Segall Bryant & Hamill LLC increased its holdings in Ingevity Co. (NYSE:NGVT - Free Report) by 33.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,185,415 shares of the company's stock after purchasing an additional 297,135 shares during the period. Segall Bryant & Hamill LLC owned 3.26% of Ingevity worth $46,231,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Ingevity by 2.0% in the first quarter. Vanguard Group Inc. now owns 3,818,520 shares of the company's stock worth $182,143,000 after acquiring an additional 75,198 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in Ingevity by 1.7% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,383,053 shares of the company's stock valued at $53,939,000 after purchasing an additional 23,497 shares during the period. Victory Capital Management Inc. increased its stake in shares of Ingevity by 1.4% in the second quarter. Victory Capital Management Inc. now owns 1,028,685 shares of the company's stock worth $44,964,000 after acquiring an additional 13,771 shares during the last quarter. Royce & Associates LP increased its position in Ingevity by 23.3% during the third quarter. Royce & Associates LP now owns 933,677 shares of the company's stock worth $36,413,000 after buying an additional 176,447 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Ingevity by 11.6% during the second quarter. Dimensional Fund Advisors LP now owns 845,912 shares of the company's stock worth $36,977,000 after buying an additional 88,026 shares during the last quarter. Institutional investors and hedge funds own 91.59% of the company's stock.
Analyst Upgrades and Downgrades
NGVT has been the subject of several research reports. BMO Capital Markets increased their target price on shares of Ingevity from $40.00 to $47.00 and gave the company a "market perform" rating in a research note on Thursday, October 31st. Oppenheimer reduced their price objective on shares of Ingevity from $58.00 to $50.00 and set an "outperform" rating on the stock in a research note on Thursday, August 1st. Wells Fargo & Company cut their price objective on shares of Ingevity from $45.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Monday, August 5th. Finally, CJS Securities upgraded shares of Ingevity from a "market perform" rating to an "outperform" rating and set a $58.00 price target on the stock in a research note on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $52.17.
View Our Latest Research Report on Ingevity
Ingevity Trading Down 1.7 %
NYSE:NGVT traded down $0.80 during midday trading on Wednesday, reaching $45.19. 72,315 shares of the stock traded hands, compared to its average volume of 267,317. The company has a debt-to-equity ratio of 6.52, a quick ratio of 1.04 and a current ratio of 1.76. Ingevity Co. has a 12 month low of $30.90 and a 12 month high of $56.29. The stock has a market capitalization of $1.64 billion, a P/E ratio of -2.96 and a beta of 1.60. The company has a fifty day moving average of $38.84 and a 200 day moving average of $42.05.
Ingevity (NYSE:NGVT - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.50. Ingevity had a negative net margin of 38.11% and a positive return on equity of 24.46%. The firm had revenue of $376.90 million for the quarter, compared to the consensus estimate of $376.95 million. During the same quarter last year, the firm posted $1.21 EPS. The business's quarterly revenue was down 15.5% compared to the same quarter last year. On average, research analysts predict that Ingevity Co. will post 2.55 EPS for the current year.
About Ingevity
(
Free Report)
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.
Featured Articles
Before you consider Ingevity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ingevity wasn't on the list.
While Ingevity currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.